- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05405673
Precisión diagnóstica de un panel de marcadores genéticos bacterianos (M3) para la neoplasia colorrectal avanzada (M3-PRO)
Un estudio transversal prospectivo para evaluar la precisión diagnóstica de un panel de marcadores genéticos bacterianos (M3) para la neoplasia colorrectal avanzada
The investigators aim to evaluate and compare the diagnostic accuracy of FIT and the novel panel of bacterial gene markers (Fn, m3, Ch and Bc) collectively named as M3, in detecting colorectal advanced neoplasia.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Colorectal cancer (CRC) is the one of the most common cancers in Hong Kong with more than 5,500 new cases annually. There is prevailing evidence of increasing trend of young onset CRC globally. Early detection and resection of pre-malignant colorectal neoplasia has shown to reduce CRC-related mortality.
Non-invasive stool tests including guaiac-based faecal occult blood tests (gFOBT) and faecal immunochemical tests (FIT) are the cornerstones of population-based CRC screening programmes. The major limitation of this widely used strategy is its unsatisfactory sensitivities for CRC (79%) and advanced adenomas (AA; 40%). The sensitivity for non-advanced adenomas is even lower than 10%. A large proportion of advanced and non-advanced adenomas will be missed by FIT alone. Therefore, identification of alternative non-invasive test with better sensitivity to detect colorectal neoplasia is warranted.
Multitarget stool DNA test and faecal microbial DNA markers appear to be promising options for CRC screening. Several bacterial gene markers have been identified by metagenome sequencing and reported to be associated with CRC, including Fusobacterium nucleatum (Fn), Clostridium hathewayi (Ch) and Bacteroides clarus (Bc). However, these molecular markers had low accuracy in distinguishing adenomas from normal tissue. Recently, a new Lachnoclostridium gene marker (labelled as 'm3') has been shown to have high diagnostic yield for the detection of colorectal adenomas. In a case-control study of 1012 subjects, a linear increasing trend of m3 level was observed from fecal samples of healthy subjects to those with adenomas and cancers. The overall sensitivity of m3 was significantly higher than FIT in detecting all adenomas (48% vs 9.3%), AA (50.8% vs 16.1%) and non-advanced adenomas (44.2% vs 0%). The diagnostic accuracy of m3 could be further enhanced by combining with a panel of fecal microbial markers composing of Fusobacterium nucleatum (Fn), Bacteroides clarus (Bc), Clostridium hathewayi (Ch) for CRC (82.3%) and adenomas (64.2%). We hypothesized that the combination of these 4 bacterial gene markers (known as M3) is more sensitive than FIT in detecting colorectal advanced neoplasia.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Subjects with average risk of colorectal neoplsia requring screening/surveillance colonoscopy
Descripción
Inclusion Criteria:
- They require elective colonoscopy for colorectal cancer screening or polyp surveillance, or investigation of symptoms (e.g. anemia, change of bowel habit, abdominal pain);
- Aged ≥18 years old;
- Written informed consent obtained.
Exclusion Criteria:
- Contraindications to colonoscopy (e.g. perforation, intestinal obstruction, unstable cardiopulmonary status);
- Contraindication to polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets);
- Known colorectal cancer or adenoma for staged procedure;
- Previous colonic resection;
- Personal history of colorectal cancer;
- Personal history of polyposis syndrome;
- Personal history of inflammatory bowel disease;
- Known pregnancy or lactation;
- Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above);
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_ONLY
- Perspectivas temporales: CROSS_SECTIONAL
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Colorectal neoplasia screening/surveillance cohort
Subjects with average risk of colorectal neoplasias requiring screening/surveillance colonoscopy |
A kind of stool test
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sensitivity of bacterial gene markers panel (M3)
Periodo de tiempo: 1 month
|
The proportion of subjects with true positive results of M3 among those with one of more advanced neoplasia detected in the index colonoscopy. |
1 month
|
|
Sensitivity of FIT/FOBT
Periodo de tiempo: 1 month
|
The proportion of subjects with true positive results of FIT among those with one of more advanced neoplasia detected in the index colonoscopy. |
1 month
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sensitivity of M3 for early-stage (stage 1) or invasive (stage 2-4) colorectal cancers
Periodo de tiempo: 1 month
|
The proportion of subjects with true positive results of M3 among those with early-stage (stage 1) or invasive (stage 2-4) colorectal cancers detected in the index colonoscopy. |
1 month
|
|
Sensitivity of FIT/FOBT for early-stage (stage 1) or invasive (stage 2-4) colorectal cancers
Periodo de tiempo: 1 month
|
The proportion of subjects with true positive results of FIT among those with early-stage (stage 1) or invasive (stage 2-4) colorectal cancers detected in the index colonoscopy. |
1 month
|
|
Sensitivity of FIT/FOBT for advanced adenomas
Periodo de tiempo: 1 month
|
The proportion of subjects with true positive results of FIT among those with one or more advanced adenomas detected in the index colonoscopy. |
1 month
|
|
Sensitivity of M3 for advanced adenomas
Periodo de tiempo: 1 month
|
The proportion of subjects with true positive results of M3 among those with one or more advanced adenomas detected in the index colonoscopy. |
1 month
|
|
Sensitivity of FIT/FOBT for all adenomas
Periodo de tiempo: 1 month
|
The proportion of subjects with true positive results of FIT among those with all advanced adenomas detected in the index colonoscopy. |
1 month
|
|
Sensitivity of M3 for all adenomas
Periodo de tiempo: 1 month
|
The proportion of subjects with true positive results of M3 among those with all advanced adenomas detected in the index colonoscopy. |
1 month
|
|
Sensitivity of FIT/FOBT for sessile serrated lesions (SSL)
Periodo de tiempo: 1 month
|
The proportion of subjects with true positive results of FIT among those with SSLs detected in the index colonoscopy. |
1 month
|
|
Sensitivity of M3 for sessile serrated lesions (SSL)
Periodo de tiempo: 1 month
|
The proportion of subjects with true positive results of M3 among those with SSLs detected in the index colonoscopy. |
1 month
|
|
Specificity
Periodo de tiempo: 1 month
|
The proportion of true negative results of M3/FOBT/FIT among those with no adenoma detected in colonoscopy |
1 month
|
|
Positive predictive value (PPV)
Periodo de tiempo: 1 month
|
The ratio of subjects truly diagnosed as positive to all those who had positive test results |
1 month
|
|
Negative predictive value (NPV)
Periodo de tiempo: 1 month
|
The ratio of subjects truly diagnosed as negative to all those who had negative test results |
1 month
|
|
Overall diagnostic accuracy
Periodo de tiempo: 1 month
|
The proportion of correctly classified subjects among all subjects |
1 month
|
|
Microbiota changes in subjects with adenomas or normal findings after polypectomy
Periodo de tiempo: 1 month
|
Microbiota change measured by qPCR or metagenomic sequencing |
1 month
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2022.170
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .